HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies

HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies

The aim of this study is to describe the prevalence of HPV types in invasive cervical cancers in Italy from 1996 to 2008. A pooled analysis of the three largest case series typed to date was performed. HPV typing was performed on paraffin-embedded slices. Molecular analyses were performed in four la...

Full description

Saved in:
Bibliographic Details
Published in:Infectious agents and cancer Vol. 7; no. 1; p. 26
Main Authors: Giorgi Rossi, Paolo, Sideri, Mario, Carozzi, Francesca Maria, Vocaturo, Amina, Buonaguro, Franco Maria, Tornesello, Maria Lina, Burroni, Elena, Mariani, Luciano, Boveri, Sara, Zaffina, Leandra Maria, Chini, Francesco
Format: Journal Article
Language:English
Published: England BioMed Central Ltd 12-10-2012
BioMed Central
BMC
Subjects:
Adenocarcinoma
Age
Cancer
Cancer vaccines
Cervical cancer
Diagnosis
Geriatrics
Human papillomavirus
Invasiveness
Multivariate analysis
Oncology, Experimental
Papillomavirus infections
Studies
Typing
Vaccination
Vaccines
Italy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study is to describe the prevalence of HPV types in invasive cervical cancers in Italy from 1996 to 2008. A pooled analysis of the three largest case series typed to date was performed. HPV typing was performed on paraffin-embedded slices. Molecular analyses were performed in four laboratories. Multivariate analyses were performed to test the associations between calendar time, age, and geographical area and the proportion of types 16/18. Out of 574 cancers, 24 (4.2%) were HPV negative. HPV 16 and 18 were responsible for 74.4% (378/508) and 80.3% (49/61) of the squamous cancers and adenocarcinomas, respectively. Other frequent types were 31 (9.5%), 45 (6.4%), and 58 (3.3%) for squamous cancers and 45 (13.3%), 31, 35, and 58 (5.0%) for adenocarcinomas. The proportion of HPV 16 and/or 18 decreased with age (p-value for trend <0.03), while it increased in cancers diagnosed in more recent years (p-value for trend < 0.005). The impact of HPV 16/18 vaccine on cervical cancer will be greater for early onset cancers. In vaccinated women, screening could be started at an older age without reducing protection.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1750-9378
1750-9378
DOI:10.1186/1750-9378-7-26